Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:16:13.094Z.
Consensus retrieved: 2026-10-06T10:19:09.297Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:16:13.094Z.
Quote observation: 2026-10-06T14:15:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937
Forward PE Ratio (N/A) = Dated Quote Price ($10.88) / Consensus Forward EPS ($-0.79)
FORWARD PE RATIO
N/A
Climb Bio, Inc.
Market Cap
$623.31M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Climb Bio, Inc. (CLYM) | $623.31M | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $620.81M | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $615.44M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $635.14M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $646.50M | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 2.97 |
| Helus Pharma Inc. (HELP)vs › | $659.20M | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $583.82M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.04M | N/A |
| Annexon, Inc. (ANNX)vs › | $667.66M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $10.88, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.79 | $-0.86 – $-0.71 | 11 | n/m |
| 2027-12-31 | $-0.98 | $-1.10 – $-0.89 | 11 | n/m |
| 2028-12-31 | $-1.38 | $-2.58 – $-0.88 | 12 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
